ERBB2 and neoplasm: In our study, 22% of HER2-positive tumours before treatment changed to HER2-negative after neoadjuvant treatment, more commonly in HER2 IHC 2+/HER2 amplified tumours, especially ASCO/CAP FISH Group 1.